Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03460821
Other study ID # ACE-III
Secondary ID
Status Completed
Phase
First received February 27, 2018
Last updated April 10, 2018
Start date March 1, 2018
Est. completion date March 31, 2018

Study information

Verified date April 2018
Source Charite University, Berlin, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the entire project was to perform a translation and cultural adaptation of the Addenbrooke's Cognitive Examination - III (ACE-III), adhering to the Translation and Cultural Adaptation of Patient Reported Outcomes Measures—Principles of Good Practice, in order to make it available to German clinicians.

Part of the translation process is the cognitive debriefing which will be performed as a survey which rates the applicability of every single item as well as of the entire Addenbrooke's Cognitive Examination - III tool.


Description:

The recent demographic developments have drastically increased the importance of developing applicable approaches to the diagnostics of dementia and the general evaluation of cognitive function. Many different tests were developed to thoroughly evaluate neurocognitive function.

The Addenbrooke's Cognitive Examination, developed in 2000, was one such tests and has served as an open source neurocognitive examination tool ever since. The current version is the Addenbrooke's Cognitive Examination III (ACE-III). The aim was to develop a tool that would be able to identify dementia in its early stages and also to differentiate between the different types of dementia.

In order to achieve reliable results, cognitive tests should be conducted in a familiar language and draw from the cultural background a participant is familiar with. The ACE-III and all its predecessors were developed in English and for an English-speaking cultural background, not directly applicable to the typical German patient. This made it necessary to perform not only a verbatim translation of test contents, but also to appropriately adapt the test content to reflect the cultural background of the typical German patient. The International Society For Pharmacoeconomics and Outcomes Research (ISPOR) - Task Force for Translation and Cultural Adaptation has developed the "Translation and Cultural Adaptation of Patient Reported Outcomes Measures—Principles of Good Practice", to ensure a consistent and rigorous methodology in the process of translating and adapting patient-reported outcomes measures.

The Principles of Good Practice consist of ten steps:

1. Preparation

2. Forward Translation

3. Reconciliation

4. Back Translation

5. Back Translation Review

6. Harmonization

7. Cognitive Debriefing

8. Review of Cognitive Debriefing Results and Finalization

9. Proofreading

10. Final Report


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date March 31, 2018
Est. primary completion date March 31, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 67 Years
Eligibility Inclusion Criteria:

- Male and female employees of the Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité Universitätsmedizin Berlin (residents, specialist physician for anesthesiology, senior physicians, medical students engaged in research projects)

.- = 18 years of age

- Experience in the field of neurocognitive testing

Exclusion Criteria:

- Insufficient knowledge of the German language

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Department of Anesthesiology and Operaitve Intensive Care Medicine, Campus Charite Mitte (CCM) and Campus Virchow - Klinikum, Charite - Universitätsmedizin Berlin Berlin

Sponsors (1)

Lead Sponsor Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of respondents who rate the questionnaire as "applicable" or "not applicable" The overall applicability of the German translation will be evaluated on a scale from 0 (not applicable) to 5 (applicable without any restrictions). A priori, a score of = 4 was defined as indicating applicability. The overall applicability will be judged by the amount of survey respondents rating the entire battery as applicable, in relation to the total number of respondents. Up to one month
Secondary Percentage of the items which are rated as "applicable" or "not applicable" Description: The applicability of each individual item will be evaluated on a scale from 0 (not applicable) to 5 (applicable without any restrictions). A priori, a score of = 4 was defined as indicating applicability. The overall applicability will be judged by the amount of survey respondents rating the entire battery as applicable, in relation to the total number of respondents Up to one month
Secondary Mean/Median applicability of the entire survey Mean/Median applicability of the entire survey will be calculated using the applicability ratings of the entire survey (as described above) Up to one month
Secondary Frequency of limiting factors of the entire Addenbrooke's Cognitive Examination - III questionnaire If participants rate the entire survey as not applicable (rating < 4) they are asked to choose a limiting factor from a predefined list. The frequency with which every limiting factor is mentioned is compiled to evaluate its impact on the entire survey Up to one month
Secondary Frequency of limiting factors of the single items If participants rate an item as not applicable (rating < 4) they are asked to choose a limiting factor from a predefined list. The frequency with which every limiting factor is mentioned is compiled to evaluate its impact on the entire survey. Up to one month
See also
  Status Clinical Trial Phase
Completed NCT04005456 - Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design N/A
Enrolling by invitation NCT06227962 - Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
Completed NCT04038788 - Add-on HD Hf-tRNS Over Bilateral DLPFC for Treating Patients With Schizophrenia N/A
Withdrawn NCT01186289 - Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery N/A
Recruiting NCT05077748 - An 18-year Follow-up Study on OSA in a Population-based Cohort
Recruiting NCT03709199 - Long Term Follow up of Children Enrolled in the REDvent Study
Recruiting NCT03606421 - CBF and NCF Changes With Brain Radiation
Recruiting NCT04458207 - Cognitive Changes and Neural Correlates After Rehabilitation of Masticatory Function in Elderly -an Intervention Study N/A
Recruiting NCT05363332 - Impact and Sequelae of High Ventilatory Drive in Critically Ill COVID-19 Patients
Recruiting NCT03886675 - Intervention With Cerebral Embolic Protection in TEVAR: Gaseous Protection N/A
Enrolling by invitation NCT04373525 - Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
Enrolling by invitation NCT04881266 - Long-Term Functional, Quality-of-Life, Neuropsychological and Cognitive Outcomes in COVID-19 Critical Illness Survivors
Completed NCT03795454 - Can Singing Kangaroo Improve Outcome of Preterm Infants N/A
Recruiting NCT05019300 - Long-term Neurocognitive and Psychiatric Consequences in Severe COVID-19 Survivors.
Not yet recruiting NCT05245903 - Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
Terminated NCT03163277 - Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) Phase 4
Not yet recruiting NCT06224088 - Neuro-cognitive Function 1 Year Post ICU Discharge Among VV ECMO Survivors
Not yet recruiting NCT06413173 - Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric) N/A
Terminated NCT03863639 - Changes in fMRI and Neurocognitive Function in Women With Pre-eclampsia
Enrolling by invitation NCT03567304 - Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine Phase 4